Zanidatamab Zovodotin

Zanidatamab Zovodotin
October 13, 2023
Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor 2 (HER2)-positive Solid Cancers
Oh et al.
Zanidatamab Zovodotin
April 17, 2023
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
Barnscher et al.
Zanidatamab Zovodotin
February 22, 2023 - February 23, 2023
European Bispecific & Multispecific Antibody Congress
Design and Functional Characterization of Zanidatamab Zovodotin (ZW49), a HER2-targeting Biparatopic Antibody Drug Conjugate in Clinical Development​
Stuart Barnscher
Zanidatamab Zovodotin
September 12, 2022
Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers
Jhaveri et al.
Zanidatamab Zovodotin
April 14, 2018 - April 18, 2018
ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
Hamblett et al.